Immunoproliferative Disorders

12 clinical trials · Condition

Record	Firm	Date
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma (NCT04309084)	Celularity Incorporated	2020-05-12
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (NCT03696784)	UNC Lineberger Comprehensive Cancer Center	2019-03-12
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676)	Juno Therapeutics, a Subsidiary of Celgene	2018-11-29
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (NCT03602157)	UNC Lineberger Comprehensive Cancer Center	2018-10-29
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT03373019)	Fudan University	2017-12-21
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (NCT02690545)	UNC Lineberger Comprehensive Cancer Center	2016-08-26
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (NCT02663297)	UNC Lineberger Comprehensive Cancer Center	2016-06-07
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL (NCT03016377)	UNC Lineberger Comprehensive Cancer Center	2012-03-22
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch (NCT03594162)	UNC Lineberger Comprehensive Cancer Center

Every clearance here is in the API, with alerts when new ones post.